Clinical study design

Cytokinetics Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022
Buildout, Investment, American College, Efficacy, European Heart Journal, Disopyramide, GLOBE, NDA, Heart failure, Safety, Food, Open-label trial, Blood, Clinical study design, Patient, Royalty Pharma, Heart, FDA, Cohort, Rationale, New Drug Application, CPET, Manuscript, Cardiology, Lists of scientists, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Atrial fibrillation, Cytokinetics, PDUFA, Risk, Exercise, Medical device, Pharmaceutical industry, HCM

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2022. Net loss for the first quarter was $89.4 million, or $1.05 per share, compared to net loss for the first quarter of 2021 of $47.1 million, or $0.66 per share. Cash, cash equivalents and investments totaled $686.1 million at March 31, 2022.

Key Points: 
  • Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022
    Continued Launch Readiness Activities and Buildout of Commercial Infrastructure in Advance of PDUFA Date of November 30, 2022 for Omecamtiv Mecarbil
    SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2022.
  • Revenues for the first quarter 2022 were $1.1 million compared to $6.5 million for the corresponding period in 2021.
  • Members of Cytokinetics senior management team will review the companys first quarter results on a conference call today at 4:30 PM Eastern Time.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Worldwide Virtual Clinical Trials Industry to 2027 - Emerging Collaborations Between Biotechnology and Clinical Research Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, April 8, 2022
Technology, Health, Clinical Trials, Other Technology, CAGR, Market share analysis, USD, Clinical study design, Strategic management, Investment, Customer support, Growth, Certification, Implication, Use, Technology, Region, COVID-19, Business Growth Fund, Value, R, Acquisition, Decision-making, Pharmaceutical industry, Retail, Medical device, Fine chemical, Dietary supplement

What are the inhibiting factors and impact of COVID-19 shaping the Global Virtual Clinical Trials Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Virtual Clinical Trials Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Virtual Clinical Trials Market?
  • What is the market share of the leading vendors in the Global Virtual Clinical Trials Market?
  • What modes and strategic moves are considered suitable for entering the Global Virtual Clinical Trials Market?

Insights on the Virtual Clinical Trials US Market to 2027 - Featuring AiCure, Covance and Everest Global Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 6, 2022
Health, Clinical Trials, State, CAGR, Market share analysis, USD, Clinical study design, Strategic management, Investment, Customer support, Growth, Certification, Implication, Use, Technology, COVID-19, Business Growth Fund, Value, R, Acquisition, Decision-making, Pharmaceutical industry, Retail, Medical device, Fine chemical, Dietary supplement, Generic drug

What is the market size and forecast of the United States Virtual Clinical Trials Market?

Key Points: 
  • What is the market size and forecast of the United States Virtual Clinical Trials Market?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the United States Virtual Clinical Trials Market?
  • What is the market share of the leading vendors in the United States Virtual Clinical Trials Market?
  • What modes and strategic moves are considered suitable for entering the United States Virtual Clinical Trials Market?

Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session

Retrieved on: 
Saturday, April 2, 2022
Blood pressure, Clinical trial, University of Pennsylvania, Patient, Disopyramide, SD, Moderation, Assistant, Clinical study design, Week, Cohort, Center, Safety, Valsalva maneuver, American College, Cardiology, Heart rate, LVOT, GLOBE, Cytokinetics, LVEF, Oxford Handbook of Clinical Medicine, SAN, Obstruction, Research and development, Mercury (element), University, Pharmaceutical industry, NYHA, HCM

All patients received up to three escalating doses of aficamten once daily (5, 10, 15 mg), titrated based on echocardiographic guidance.

Key Points: 
  • All patients received up to three escalating doses of aficamten once daily (5, 10, 15 mg), titrated based on echocardiographic guidance.
  • The doses of aficamten employed were the same as those used in Cohort 1 of REDWOOD-HCM.
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

Retrieved on: 
Saturday, April 2, 2022
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, People, CGRP, Angioedema, Disability, Caregiver, Barbiturate, MMD, Research, Eptinezumab, Neurological disorder, Hives, Poster, MOH, JAMA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LUN, Medicine, History, IV, Marketing, American Academy of Neurology, Disease, YLD, Nausea, Cluster headache, Lists of diseases, Rash, Hypersensitivity, Vomiting, Headache, Safety, Anaphylaxis, Disease burden, Month, AHM, MHD (rapper), Intravenous therapy, CM, American Academy, Calcitonin, Common, FDA, Patient, PGIC, Global Burden of Disease Study, Excipient, Woman, Food, Week, Clinical study design, AAN, Pharmaceutical industry, Poultry, Copper, Vaccine, Medical device, Migraine, Neurology, Lundbeck

The proportion reporting no headache and no AHM use increased by 33.8 percentage points and 23.6 percentage points for VYEPTI and placebo groups, respectively.

Key Points: 
  • The proportion reporting no headache and no AHM use increased by 33.8 percentage points and 23.6 percentage points for VYEPTI and placebo groups, respectively.
  • This is the first study to evaluate the efficacy and safety of VYEPTI in people with episodic cluster headache.
  • The efficacy and safety of VYEPTI were demonstrated in two phase 3 clinical trials; episodic migraine in PROMISE 1 and chronic migraine in PROMISE 2.
  • The safety of VYEPTI was evaluated in 2,076 patients with migraine who received at least one dose of VYEPTI.

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo

Retrieved on: 
Thursday, March 24, 2022
Private Securities Litigation Reform Act, Comparative effectiveness research, Research, Center, Twitter, American College, Cardiology, Intellectual property, GLOBE, Medicine, Cardiomyopathy, University, Heart failure, Security (finance), Thomas Jefferson National Accelerator Facility, Cohort, Amyotrophic lateral sclerosis, Sale, Clinical study design, Safe harbor, Act, Institute, U.S. Securities and Exchange Commission, Cytokinetics, Hypertrophic cardiomyopathy, Effect, Safety, Patent, University of Glasgow, ALS, Mechanics, Muscle weakness, Multisystemic smooth muscle dysfunction syndrome, Hospital, patients, health, territories, SAN, FDA, LinkedIn, The Act, University of Pennsylvania, Pharmacology, Assistant, Facebook, Intensity, Contractility, YouTube, Pharmaceutical industry, Hospital, Amusement arcade, HCM, Patient

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 71st Annual Scientific Session & Expo (ACC.22) taking place in Washington, D.C. from April 2, 2022 - April 4, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 71st Annual Scientific Session & Expo (ACC.22) taking place in Washington, D.C. from April 2, 2022 - April 4, 2022.
  • For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter , LinkedIn , Facebook and YouTube .
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia

Retrieved on: 
Tuesday, March 22, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Pupil, Therapy, LinkedIn, Smartphone, BRIO, Glaucoma, Research, Wound healing, Reading, Brimonidine, Retina, Carbachol, Prevalence, American Academy of Optometry, Safety, Reduction, Presbyopia, Time, Ageing, Clinical study design, American Academy, Hardship, Visu, McLaurin, Eye, Instagram, Insurance, Patient, Pharmaceutical industry, Telescopic sight, Optometry, New Drug Application, Twitter, PRESBYOPIA, VISUS THERAPEUTICS

The initiation of the BRIO trials follows compelling topline data from the companys Phase 2 VIVID clinical study, which demonstrated two preservative-free formulations, BRIMOCHOL PF and Carbachol PF, were well tolerated and met clinical outcomes to support advancement into pivotal trials.

Key Points: 
  • The initiation of the BRIO trials follows compelling topline data from the companys Phase 2 VIVID clinical study, which demonstrated two preservative-free formulations, BRIMOCHOL PF and Carbachol PF, were well tolerated and met clinical outcomes to support advancement into pivotal trials.
  • The initiation of our first Phase 3 trial is a momentous occasion for Visus Therapeutics.
  • The BRIO-I and BRIO-II trials are designed to study BRIMOCHOL PF, a novel, fixed-dose combination of carbachol and brimonidine tartrate, and a proprietary, preservative-free formulation of carbachol monotherapy.
  • In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma and age-related macular degeneration.

Announcing Olympus as a 2022 Edison Award Finalist

Retrieved on: 
Monday, March 28, 2022
Universe, Urine, Emergency Medical Treatment and Active Labor Act, Treatment, Medicine, Hematuria, Multimedia, Clinical study design, Prostate, Urinary tract infection, Edison Award, Program, Science, Man, Thomas Edison, Edison Awards, Dysuria, Olympus, Association for the Behavioral Sciences and Medical Education, Quality of life, BPH, Safety, Laparoscopy, Olympus Corporation, Physician, Solution, Endoscopy, Patient, Medical device, Medical imaging, Pharmaceutical industry

CENTER VALLEY, Pa., March 28, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today it isa 2022 Edison Award Finalist for its iTind Procedure, which is nominated within the Science and Medical category for Medical Treatments.

Key Points: 
  • CENTER VALLEY, Pa., March 28, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today it isa 2022 Edison Award Finalist for its iTind Procedure, which is nominated within the Science and Medical category for Medical Treatments.
  • The Edison Awards recognize innovations and innovators whose solutions make a positive impact in the world.
  • Edison Award finalists will be honored at the 2022 Edison Awards held April 21st, at the Luminary Hotel in Ft. Myers, Florida.
  • The Edison Awards is a program conducted by Edison Universe, a 501(c)(3) charitable organization.

Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)

Retrieved on: 
Friday, March 11, 2022
Drug development, Patient, Risk, CET, Neuroscience, Dementia, Meta-analysis, Confusion, Private Securities Litigation Reform Act, Health, Plasma, Brain, Population, Climate, Disease, Nobel Prize, LinkedIn, Safety, Biomarker, Swelling, Bleeding, International Conference on Emerging Infectious Diseases, Failure, Dizziness, Intellectual property, GLOBE, Nausea, Magnetic resonance imaging, Biotechnology, MRI, Lists of diseases, Causality, EDT, Pathology, Research, Conference, Clinical study design, ARIA, News, U.S. Securities and Exchange Commission, Allergy, Instrumental variables estimation, Treatment, BIIB, Medication, ID, Nasdaq, Multiple sclerosis, Twitter, Spinal muscular atrophy, Science, Social media, Participation, COVID-19, YouTube, Headache, Pharmaceutical industry, Medical imaging, Communications satellite, Facebook, Biogen, Eisai

These data include analyses of treatment effect on biomarkers of Alzheimers disease in the long-term extension studies, with over two years of Phase 3 data.

Key Points: 
  • These data include analyses of treatment effect on biomarkers of Alzheimers disease in the long-term extension studies, with over two years of Phase 3 data.
  • ; P225 / #1868, Virtual Poster Presentation] Tuesday, March 15, starting at 8:00 a.m. CET; 3:00 a.m. EDT
    ADUHELM is indicated for the treatment of Alzheimers disease.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

DIGITAL DIAGNOSTICS AND BAXTER ANNOUNCE NEW PARTNERSHIP TO ADVANCE DIABETIC RETINOPATHY DETECTION

Retrieved on: 
Wednesday, March 9, 2022
People, Risk, Partnership, Control, Adoption, Ranibizumab, Image sensor, Disease, Diabetic retinopathy, LinkedIn, Vitreous hemorrhage, FDA, AI, Diabetes, The American Journal of Managed Care, Vitrectomy, Multimedia, Severe cognitive impairment, Critical care, Fundus, Artificial intelligence, American Journal, Doctor of Philosophy, Type 1 diabetes, Macular edema, SEC, Hospital Insurance and Diagnostic Services Act, EMR, Welch Allyn, Laser, Research, Ophthalmology, Lists of disasters, MD, News, JAMA, Baxter International, Caregiver, Retinal, Clinical study design, Twitter, Hatef Higher Education Institute, HEDIS, Form 10-K, Acquisition, Hospital, Technology, COO, Diagnosis, Laser coagulation, Medical device, Medical imaging, Pharmaceutical industry, 3D printing, Patient, Hillrom, Facebook, Baxter

The partnership includes plans to offer Digital Diagnostics' industry-leading IDx-DR autonomous AI software as a diagnostic service combined with the Welch Allyn RetinaVue 700 Imager .

Key Points: 
  • The partnership includes plans to offer Digital Diagnostics' industry-leading IDx-DR autonomous AI software as a diagnostic service combined with the Welch Allyn RetinaVue 700 Imager .
  • Digital Diagnostics created IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (including diabetic macular edema) at the point-of-care.
  • Our partnership with Digital Diagnostics is integral in expanding our connected care diagnostics portfolio."
  • The agreement between Baxter and Digital Diagnostics is exclusive in the U.S. and non-exclusive outside the U.S.